Abstract
We determined the relationship between levels of serum cystatin C or serum creatinine (s‐Cr) and prognostic stages of type 2 diabetic nephropathy. Serum samples from 174 patients with type 2 diabetes were obtained from Juntendo University Hospital, Tokyo and Juntendo Urayasu Hospital, Chiba, Japan. They were classified into four groups according to the Report of the Ministry of Health and Welfare of Japan as follows: Stage I (normoalbuminuric stage), Stage II (microalbuminuric stage), Stage IIIA (macroalbuminuric stage without renal dysfunction), Stage IIIB (macroalbuminuric stage with renal dysfunction), and Stage IV (renal failure stage). Among these patients, 68 were Stage I, 29 Stage II, 32 Stage IIIA, 17 Stage IIIB, and 28 Stage IV. The levels of serum cystatin C were measured using the Dade Behring Cystatin C assay with automated Dade Behring Nephelometer II (BNII) (Dade Behring Marburg GmbH, Germany). The mean levels of serum cystatin C in Stage IIIA were significantly higher than those in Stage I or II (P<0.00001, P<0.0005, respectively). The mean levels of serum cystatin C in Stage IIIB and Stage IV were also significantly higher than those in Stage I (P<0.00001). However, the mean levels of serum creatinine (s‐Cr) in Stage IIIA were not significantly higher than those in Stage I or II. The levels of s‐Cr in Stage IIIB and Stage IV were significantly higher than those in Stage I (P<0.00001). Receiver operating characteristic (ROC) plots demonstrated that the area under the curve (AUC) of cystatin C (0.76) was greater than that of s‐Cr (0.66). As an early prognostic marker of type 2 diabetic nephropathy, serum cystatin C was better than s‐Cr in terms of sensitivity and specificity. It appears that the levels of serum cystatin C may predict early prognostic stages of patients with type 2 diabetic nephropathy. J. Clin. Lab. Anal. 17:164–167, 2003. © 2003 Wiley‐Liss, Inc.
Keywords: serum cystatin C, s‐Cr, Ccr, type 2 diabetic nephropathy, GFR
REFERENCES
- 1. Barret AJ, Davies ME, Grubb A. The place of human γ‐trace (cystatin C) amongst the cystein proteinase inhibitors. Biochem Biophys Res Commun 1984;120:631–636. [DOI] [PubMed] [Google Scholar]
- 2. Simonsen O, Grubb A, Thysell H. The blood serum concentration of cystatin C (γ‐trace) is a measure of the the glomerular filtration rate. Scand J Clin Lab Invest 1985;45:97–101. [DOI] [PubMed] [Google Scholar]
- 3. Newman DJ, Thakkar H, Edwards RG, et al. Serum cyatatin C measured by automated immunoassay: a more sensitive marker of changes in GFR than serum creatinine. Kidney Int 1995;47:312–318. [DOI] [PubMed] [Google Scholar]
- 4. Tomino Y, Suzuki S, Gohda T, et al. Serum cystain C may predict the prognostic stages of patients with IgA nephropathy prior to renal biopsy. J Clin Lab Anal 2001;15:25–29. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 5. Shimizu‐Tokiwa A, Kobata M, Io H, et al. Serum cystatin C is a more sensitive marker of glomerular function than serum creatinine. Nephron 2002;92:224–226. [DOI] [PubMed] [Google Scholar]
- 6. Report of the Ministry of Health and Welfare of Japan (Japanese( . Stage classification of diabetic nephropathy. Ministry of Health and Welfare of Japan, editor. Tokyo: 1991; pp 251–256.
- 7. Erlandsen EJ, Randers E, Kristensen JH. Evaluation of the Dade Behring Latex Cystatin C assay on the Dade Behring Nephelometer II System. Scand J Clin Lab Invest 1999;59:1–8. [DOI] [PubMed] [Google Scholar]
- 8. Ohara T, Nakai K, Orisaka M, Itoh T, Saito K, Itoh K. A trial for establishing reference intervals of serum cystatin C in normal individuals (Japanese). Medicine and Pharmacology 2000;43:835–844. [Google Scholar]
- 9. Kurokawa K. Classification of renal dysfunction In: Guidelines for daily living and diet therapy in patients with renal diseases (Japanese). Japanese Society of Nephrology, editor. Tokyo: Tokyo Igakusha; 1998. p 44. [Google Scholar]